Robert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVPGet Free Report) COO Robert Ticktin sold 23,151 shares of the business’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $24,540.06. Following the sale, the chief operating officer directly owned 98,695 shares of the company’s stock, valued at approximately $104,616.70. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

PMV Pharmaceuticals Trading Up 10.0%

NASDAQ:PMVP opened at $1.21 on Friday. The firm’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $1.19. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82. The firm has a market capitalization of $62.86 million, a price-to-earnings ratio of -1.03 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVPGet Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. On average, analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

Check Out Our Latest Research Report on PMVP

Institutional Investors Weigh In On PMV Pharmaceuticals

Several hedge funds have recently modified their holdings of PMVP. JPMorgan Chase & Co. lifted its position in PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company’s stock worth $37,000 after acquiring an additional 23,559 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in PMV Pharmaceuticals in the fourth quarter valued at approximately $53,000. Squarepoint Ops LLC raised its stake in shares of PMV Pharmaceuticals by 68.7% during the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company’s stock valued at $110,000 after purchasing an additional 29,722 shares during the period. Northern Trust Corp lifted its position in shares of PMV Pharmaceuticals by 23.2% during the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock worth $162,000 after purchasing an additional 20,190 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of PMV Pharmaceuticals by 44.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company’s stock worth $305,000 after purchasing an additional 62,200 shares in the last quarter. 90.20% of the stock is currently owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Company Profile

(Get Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

Featured Stories

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.